Anti-seizure Therapy NT102 Wins FDA’s Orphan Drug Status

Anti-seizure Therapy NT102 Wins FDA’s Orphan Drug Status

312090

Anti-seizure Therapy NT102 Wins FDA’s Orphan Drug Status

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Neuroene Therapeutics‘ NT102, a potential anti-seizure therapy for Dravet syndrome. NT102, given orally, has been shown to prevent seizures in several animal models, with “excellent protection” against such attacks in Dravet syndrome, according to Neuroene. Orphan drug status is awarded by the FDA to encourage the development of therapies for rare and serious diseases, through benefits such as seven years of market exclusivity upon approval…

You must be logged in to read/download the full post.